RevIT™ AAV Enhancer: Rev-Up AAV Genome Production In Upstream Manufacturing

By Becky Reese, Jennifer Swanson, Austin Storck and Laura Juckem, Mirus Bio LLC, Madison, WI USA

Mirus Bio has developed an enhancer of adeno-associated virus (AAV) production, called RevIT™ AAV Enhancer, which could significantly reduce the manufacturing costs of AAV-based gene therapies. These therapies are currently among the most expensive drugs on the market, partly due to inefficient production methods. The enhancer can be used with TransIT-VirusGEN® Transfection Reagent or conventional polymeric transfection reagents to produce higher genome titers in suspension HEK 293 cells, and allows for the use of lower amounts of plasmid DNA (pDNA), a key cost-saving opportunity. The enhancer has been shown to increase AAV genome titers across multiple serotypes and transfection platforms, and can be easily integrated into existing AAV manufacturing workflows. By increasing recombinant AAV titers, the enhancer can help reduce upstream manufacturing costs and lower the cost per therapeutic dose.